학술논문
Real‐world data on the effectiveness, safety and drug survival of dupilumab: an analysis from the TREATgermany registry.
Document Type
Article
Author
Stölzl, Dora; Sander, Nicole; Heratizadeh, Annice; Haufe, Eva; Harder, Inken; Abraham, Susanne; Heinrich, Luise; Kleinheinz, Andreas; Wollenberg, Andreas; Weisshaar, Elke; Schäkel, Knut; Ertner, Konstantin; Wiemers, Franca; Wildberger, Julia; Worm, Margitta; von Kiedrowski, Ralph; Effendy, Isaak; Asmussen, Andrea; Augustin, Matthias; Pawlak, Mario
Source
Subject
*MEDICATION safety
*CLINICAL trials
*
Language
ISSN
0007-0963
Abstract
This interim analysis from the atopic dermatitis registry TREATgermany shows robust long-term efficacy, favourable safety and high persistence of dupilumab under real life conditions. The TREATgermany registry is one of the largest AD registries worldwide with currently more than 1400 patients with moderate-to-severe AD followed up prospectively.[[5]] In this interim analysis we aimed to analyse the real-world long-term effectiveness and safety and the drug survival of dupilumab compared with ciclosporin. Baseline characteristics, disease severity and treatment history of patients with atopic dermatitis included in the German AD Registry TREATgermany. [Extracted from the article]